v
Search
Advanced

Publications > Journals > Future Integrative Medicine > Article Full Text

  • Review Article
  • OPEN ACCESS

Medicinal Plant Extracts and Herbal Formulations: Plant Solutions for the Prevention and Treatment of COVID-19 Infection

  • Damodaran Sruthi1,* ,
  • Janardhanan Pallikere Jishna2,
  • Menamadathil Dhanalakshmi3,
  • Shashikala Paranthaman Deepanraj4 and
  • Chelliah Jayabaskaran1
 Author information  Cite
Future Integrative Medicine   2023;2(4):216-226

doi: 10.14218/FIM.2023.00079

Abstract

The highly valued area of traditional medicine includes medicinal plants and the chemical compounds found in them that have therapeutic potential as effective remedies for a variety of health issues. However, with respect to their active compounds and therapeutic value, many medicinal plants from various environments fall under the category of being underexplored. Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), was initially presented in November 2019. It was eventually labeled a pandemic, with an alarming number of deaths (6.987 million) and is still active. Alternative therapies are receiving more attention as a means of improving immunity and managing symptoms over the long term, despite the well-established scientific community’s quick success in implementing COVID-19 vaccinations. As an alternative strategy for COVID-19 management, traditional medicine therapies that comprise medicinal plants and extracts, formulations, and bioactive metabolites are currently receiving much interest. The usefulness of these herbal medicine interventions to manage COVID-19 infection has been the subject of recent studies, which are discussed here. In conclusion, we propose using plant extracts and their formulations as an alternative approach to treat COVID-19. This review may also instigate the development of anti-SARS-CoV-2 prophylactics from the active phytochemicals of these extracts.

Keywords

Traditional medicine, Herbal extracts, Formulations, COVID-19

Introduction

Since the initial detection of coronavirus disease 2019 (COVID-19) in November 2019, the disease has persisted and spread globally as a pandemic. The initial uncertainties and worries surrounding this outbreak have been addressed as the newly created vaccines are successfully used going forward and as worldwide treatment procedures become more established. However, this virus is still infecting many people with different waves, and it remains unclear how long it will remain prevalent. Additionally, certain underdeveloped nations may not be able to apply the internationally recognized treatment modalities due to insufficient medical resources.1 The virus that causes COVID-19, severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has continued to evolve, and several variants like Omicron (B.1.1.529) and its subvariants (BA.1, BA.2, BA.3, BA.4, and BA.5) have emerged due to mutation. Omicron recombinant subvariants (XBD, XBB, XBF, etc.) also have been developed. These variants have created different waves and COVID-19 surges in different parts of the world. The variants BA.2 and BA.2.38 in India, BF.7 and XBB.1.5 in China and the USA are examples of such cases.2–6 Therefore, strategies for enhancing immunity and managing symptoms over the long term are required in addition to the ongoing strategies to avoid becoming infected. According to the medical conditions of each nation, herbal medicine interventions, which comprise phytochemicals, medicinal plant extracts, and herbal formulations, can be established as an alternative option for COVID-19. Approximately 80% of people worldwide still turn to traditional treatments for their medical problems.7 In different countries, spicy herbs and medicinal plants with enormous potential are a part of their diet, which helps them to survive different ailments and reduce the impact of COVID-19.8,9 Hence, the use of herbal remedies has been advised for COVID-19 prevention as well as treatment.10 Even in the early phases of the COVID-19 epidemic, China gave herbal therapy prominence, and 90% of the patients who received treatment recovered.11,12 The Chinese traditional medicines Lianhuaqingwen and ShufengJiedu have also been advocated for COVID-19 due to their efficacy against SARS-CoV-1 and influenza A virus subtype (H1N1).13 India holds the unique distinction of having its own recognized traditional medicine; this system, which is predicated on certain medical beliefs, offers a way to achieve a healthier way of life with traditional and accepted ideas about preventing illness and enhancing well-being. The conventional applications of Indian medicinal herbs and herbal preparations can thus be repurposed to provide new therapeutic strategies for COVID-19 prevention. Numerous well-known immunity-modulating Indian traditional plants and formulations have been used for centuries to treat allergies and respiratory problems. Such formulations for COVID-19 management have been specified and recommended by the Ministry of AYUSH of the Government of India. Three nations-South Korea, China, and India-have released guidelines regarding traditional therapies for the management and prevention of COVID-19.14 Recently, with the aid of a clinical study, the potential of the herbomineral drug fifatrol to alleviate the symptoms of SARS-CoV-2 (omicron variant) infection in the North Indian population has been established.15 We have previously published a review article covering the curative potential of phytochemicals on COVID-19 infection.2

In this review, an attempt is put forward to explore the potential applications of medicinal herbs, their extracts, and formulations in the prevention of COVID-19 infection. Active phytochemicals, including both primary and secondary metabolites, with great health advantages are found in abundance in medicinal plant extracts and formulations. Among them, secondary metabolites (terpenoids, alkaloids, and phenolics) have been extensively researched for their potential medicinal uses, and some of them have been developed into natural product medications. To mitigate the current risk of COVID-19, it is crucial to take these natural sources into account to identify natural solutions against COVID-19 as well as to develop their active ingredients as COVID-19 prophylactics. Hence, this review is instructive because it highlights these aspects.

Methods

The present state of research on medicinal herbs and COVID-19 infection is reviewed thoroughly in this article. For this review article, a literature search was conducted using PubMed Central, Google Scholar, and ScienceDirect. The keywords used were as follows: COVID-19; traditional medicine and COVID-19; plant extracts on COVID-19; CAM and COVID-19; herbal medicine and COVID-19; AYUSH and COVID-19; medicinal plants and COVID-19; herbal formulations for COVID- 19 and natural products against COVID-19. The botanical components of the selected formulations and their medicinal potential were also searched. The article search was carried out from January 2022 to June 2023, and the collected articles underwent screening. Articles that adhered to the objectives of this review underwent additional screening and were meticulously summarized (Fig. 1).

Study flow diagram.
Fig. 1  Study flow diagram.

CAM, complementary and alternative medicine.

SARS CoV-2

On 11 March 2020, COVID-19 was officially declared a global pandemic by the World Health Organization.16 The virus that causes COVID-19, SARS-CoV-2, started spreading rapidly at the end of 2019 and, as of now (December 18, 2023), there are 772,386,069 confirmed cases of COVID-19 and 6,987,222 deaths due to COVID-19 worldwide.17 As a result of asymptomatic instances that could aid in the spread of the pandemic, the true number of infected individuals is likely greater than the reported number.18 SARS-CoV-2 is a single-stranded RNA virus that belongs to the family Coronaviridae and the order Nidovirales. SARS-CoV-2 has genetic structural similarity to that of SARS-CoV and Middle East respiratory syndrome-related coronavirus (MERS-CoV).18,19 Four structural proteins, including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins, are present in SARS-CoV-2. The virus has a genetic makeup of 13–15 (12 functional) open reading frames (ORFs) that have approximately 30,000 nucleotides. The genome has 11 protein-coding genes with 12 expressed proteins. The genomic structure of the ORFs closely resembles that of SARS-CoV and MERS-CoV. The ORFs 1a and 1b code for the polyproteins pp1a and pp1ab, respectively. Virally encoded proteinases further process these polyproteins to produce 16 proteins that are highly conserved across all CoVs in the same family.19 The S protein promotes host-cell attachment, whereas the envelope protein plays a role in virus assembly, host-cell membrane permeability, and virus–host cell interaction. The membrane protein is known to be the main organizer of the coronavirus assembly process, while the nucleocapsid protein takes part in the helical ribonucleocapsid complex processing.19–21 It has been demonstrated that there are six mutations in the genome of SARS CoV-2, with three in the ORF1ab gene, two in the S gene, and one in ORF7b and ORF 8. Usually, SARS-CoV-2 enters the human body via the nose, mouth, or eyes.20 The SARS-CoV-2 S glycoprotein has a receptor-binding domain that can identify the target receptor. For SARS-CoV-2, the receptor angiotensin-converting enzyme-2 (ACE2) is preferred.22 Meanwhile, enzymes such as cathepsin or transmembrane protease serine 2 (TMPRSS2) help in the hydrolysis of the S protein, resulting in membrane fusion and the release of viral nucleotides into the host cytoplasm. As a continuation, different molecular mechanisms are employed to build the new RNA and the proteins of the virus that make up its envelope. These receptors, proteases, and the proteins involved in the replication and proliferation of the virus are great targets for antiviral prophylactics.18 Proteases, mainly chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro), nonstructural protein 12, and RNA-dependent RNA polymerase are some of the main targets.18,19 There are three distinct phases of SARS-CoV-2 viral infection: the asymptomatic phase, the nonsevere symptomatic phase, and the severe infection period.20 Although the mechanism underlying COVID-19 is not yet known, patients infected with this virus exhibit nonspecific symptoms that can vary from asymptomatic to deadly pneumonia and even fatality. The most typical signs, which are comparable to those of SARS-CoV and MERS-CoV infections, include fever, dyspnea, nonproductive cough, fatigue, myalgia, diarrhea, normal or reduced leukocyte counts, lung damage, and radiographic evidence of pneumonia.14 Although SARS-CoV and the novel SARS-CoV-2 share a striking amount of similarities, the latter is spreading more quickly than the former, which might be due to the structural variations of the S proteins.23

Medicinal plant extracts and herbal formulations inhibiting SARS-CoV-2: Possible mechanism of action

Medicinal plant extracts and formulations contain vast amounts of active compounds with enormous health benefits. These phytomolecules include both primary and secondary metabolites. Among these, secondary metabolites, such as phenolics, alkaloids, and terpenoids, are widely studied for their therapeutic potential including antiviral activity, and some of them have emerged as natural product drugs. Hence, it is important to consider these natural sources to address the current threat of COVID-19, and researchers have started to concentrate on this topic. The medicinal plant extracts and herbal formulations containing highly active phytochemicals likely inhibit SARS-CoV-2 mainly through 3CLpro, PLpro, TMPRSS2, ACE2 receptor, RNA-dependent RNA polymerase, and heat shock protein A5 (Fig. 2). The nonstructural proteins 3CLpro and PLpro, which are encoded in the SARS-CoV-2 genome, are crucial for the replication of the virus. TMPRSS2 is the host enzyme that allows entry of the virus into the host cells. ACE2 is a functional receptor for SARS-CoV that contributes to S protein-mediated infection. RNA-dependent RNA polymerase is a crucial viral replicase that catalyzes the synthesis of complementary RNA strands using the viral RNA template. Heat shock protein A5 is the host cell receptor that is recognized by the S protein of the virus.2,24 Thus, these can be useful targets for developing prophylactics from natural sources. We have published a review article related to studies on phytochemicals that inhibit COVID-19 through these targets.2

Schematic representation of medicinal plant interventions and their possible targets to prevent COVID-19.
Fig. 2  Schematic representation of medicinal plant interventions and their possible targets to prevent COVID-19.

ACE2, angiotensin-converting enzyme-2; COVID-19, coronavirus disease 2019; HSPA5, heat shock protein A5; PLpro, papain-like protease; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe acute respiratory syndrome-related coronavirus 2; TMPRSS2, transmembrane protease serine 2; 3CLpro, chymotrypsin-like protease.

Medicinal plant extracts on COVID-19 infection

The most important sources of biomolecules that can be screened from plant parts are thought to be plant extracts. Such biomolecules are extracted from medicinal plants by employing a variety of extraction techniques and solvents.25 Many researchers have studied and recognized the beneficial effect of traditional medicinal plants about their extracts and formulations to manage human SARS-CoV-2. A remarkable inhibitory effect of the ethanolic extract from Psoralea corylifolia seeds was established against PLpro of SARS-CoV, with a low half-maximal inhibitory concentration (IC50) value of 15 µg/mL.26 The anti-SARS-CoV-PLpro and 3CLpro effects of ethanolic extract from Salvia miltiorrhiza (88% and 60% inhibition for PLpro and 3CLpro, respectively, at an extract concentration of 30 µg/mL) and the anti-SARS-CoV-3CLpro activity of ethanolic extract from Torreya nucifera leaves (62% at 100 µg/mL) have also been reported.27,28 The SARS-CoV-2 genome encodes two nonstructural proteins, 3CLpro and PLpro, which are essential for viral replication and may enable researchers to concentrate on these proteins as possible candidates for the development of therapeutics against SARS-CoV-2 infection.24 Proteins involved in the life cycle of SARS-CoV-2 may be good targets for antiviral medications. As a result, SARS-CoV-2 infection may be prevented by drugs that can work as an inhibitor against these proteins.21 Using a cell-based assay, the anti-SARS-CoV effects of 200 Chinese herbal extracts were evaluated. Among these extracts, six of them (Dioscorea batatas, tuber; Cassia tora, dried seed; Gentiana scabra, dried rhizome; two extracts of Cibotium barometz, dried rhizomes; and Taxillus chinensis, dried stem with leaf) effectively inhibited the growth and replication of SARS-CoV at concentrations between 25 and 200 µg/mL. This study revealed that the extracts of D. batatas tuber (IC50: 44 µg/mL) and C. barometz rhizome (IC50: 39 µg/mL) noticeably inhibited SARS-CoV-3CLpro protein.29 In addition, an in-house library of compounds from the rhizomes of Alpinia officinarum, Zingiber officinale, and Curcuma longa was prepared, and their inhibitory effects against SARS-CoV-2-PLpro were studied through in-silico docking. The results indicated that eight phytochemicals from A. officinarum and Z. officinale demonstrated a strong binding affinity for the SARS-CoV-2-PLpro conformer.30 These findings highlighted the fact that plant extracts are a source of active molecules that can act as COVID-19 prophylactics. We have already published a review article explaining the potential of different phytomolecules on COVID-19 management.2 A recent computational study also has revealed that vitamin B12 is more efficient than other vitamins against almost all drug targets of SARS-CoV-2.31 A search for the most potent natural product drug against SARS-CoV-2 through in-silico methods including molecular docking, properties, as well as aquatic and nonaquatic toxicity studies has been conducted and found dieckol as the most potent bioactive compound.32 Moreover, clinical trials regarding the potential of natural products to halt the progression of COVID-19 have been reported. The efficacy of seed oil from Nigella sativa, which is known for immune-boosting properties and antiviral activity, was investigated in hospitalized adult COVID-19 patients through an open-label randomized clinical trial. Faster recovery of symptoms with N. sativa seed oil supplementation than usual care alone for patients with mild COVID-19 infection was noticed.33Table 1 lists the reported medicinal plants against COVID-19 infection.26–29,33

Table 1

Medicinal plants (in terms of their extracts/oil) effective against COVID-19 infection

Source plantPlant PartPlant extract/ oilReferenceSARS-CoV protein inhibited
Cassia toraDried seedContinuous extraction with water, ethanol, methanol, and n-hexane293CLpro
Cibotium barometzDried rhizomeContinuous extraction with water, ethanol, methanol, and n-hexane293CLpro
Dioscorea batatasTuberContinuous extraction with water, ethanol, methanol, and n-hexane293CLpro
Gentiana scabraDried rhizomeContinuous extraction with water, ethanol, methanol, and n-hexane293CLpro
Nigella sativaSeedSeed oil33Clinical trial on COVID-19 patients
Psoralea corylifoliaSeedEthanol extract26PLpro
Salvia miltiorrhizaRootEthanol extract27PLpro and 3CLpro
Taxillus chinensisDried stem, with leafContinuous extraction using water, ethanol, methanol, and n-hexane293CLpro
Torreya nuciferaLeafEthanol extract283CLpro

COVID-19, coronavirus disease 2019; PLpro, papain-like protease; SARS-CoV, severe acute respiratory syndrome-related coronavirus; 3CLpro, chymotrypsin-like protease.

Herbal formulations on COVID-19 infection

AYUSH formulations

The traditional medical system in India is among the most ancient and has a pivotal role in health care services. There is a myriad of medicinal plants in India with indispensable therapeutic values, and they are also an essential part of many traditional formulations such as Chyawanprash and Triphala. Since ancient times, medicinal plants like ginger, ashwagandha, cinnamon, tulsi, turmeric, and amla have long been utilized as herbal treatments for a variety of illnesses.14

The recognized traditional medicines of India including Ayurveda, Yoga, and Siddha along with the alternative medicines Unani and Homeopathy, which flourished in India, form AYUSH.34 Natural products originating from plants, animals, or minerals are the basis for the pharmacological modalities of these systems. So, if we use such herbal medications in prescribed doses by following the usage guidelines, these traditional medicines are safe to use and can cure many diseases.35 Many traditional AYUSH formulations, well known for immunomodulation, have been in practice for centuries against respiratory tract diseases and allergic problems. Such formulations are listed and recommended by the Ministry of AYUSH of the Government of India for their prophylactic uses for COVID-19 management and include Ayurvedic, Unani, and Siddha approaches.14 With the technical assistance of the Indian Council of Medical Research, the Ministry of AYUSH, the Council of Scientific and Industrial Research, and the Ministry of Health and Family Welfare, clinical trials in India for AYUSH formulations like Yashtimadhu, AYUSH-64, and Ashwagandha have been initiated on patients and individuals who have close contact with those with COVID-19.14 The formulations from Ayurveda, Unani, and Siddha recommended by AYUSH for the management of COVID-19 are summarized in Table 2.14,36–85

Table 2

AYUSH-recommended formulations for COVID-19 management

FormulationIngredientsTherapeutic potential of ingredients/formulationReferences
Ayurvedic formulations
AYUSH KwathCinnamomum zeylanicum, Ocimum sanctum, Piper nigrum, Zingiber officinaleAntileishmanial, immunomodulatory, antiviral, and antiproliferative36–41
Samshamani VatiTinospora cordifoliaAntipyretic, immunomodulatory, antiviral, and anti-inflammatory42–45
AYUSH-64Alstonia scholaris, Caesalpinia crista, Picrorhiza kurroa, Swertia chirayitaAntiviral, anti-asthmatic, immune-boosting, and antimalarial46–51
Agasthya HareetakiAchyranthes aspera, Aegle marmelos, Clerodendron serratum, Convolvulus pluricaulis, Desmodium gangeticum, Gmelina arborea, Hedychium spicatum, Hordeum vulgare, Inula racemosa, Mucuna prurita, Oroxylum indicum, Piper chaba, Piper longum, Plumbago zeylanica, Premna mucronata, Sida cordifolia, Solanum indicum, Solanum surattense, Stereospermum suaveolens, Terminalia chebula, Tribulus terrestris, Uraria pictaAntiviral, anti-oxidant, anti-asthmatic, anti-inflammatory, and immunomodulatory52–61
AnuthailaAegle marmelos, Aquilaria agallocha, Asparagus racemosus, Berberis aristata, Cedrus deodara, Cinnamomum tamala, Cinnamomum zeylanicum, Coleus vettiveroides, Cyperus rotundus, Cyperus scariosus, Desmodium gangeticum, Elettaria cardamomum, Embelia ribes, Glycyrrhiza glabra, Hemidesmus indicus, Leptadenia reticulata, Nelumbo nucifera, Nymphaea stellata, Pluchea lanceolata, Santalum album, Sesamum indicum, Solanum indicum, Solanum surattense, Uraria Picta, Vetiveria zizanioides, Vitex negundoEffective against asthma, allergic response, bronchitis, cough, throat trouble, fever, migraine, malaria, respiratory infections, and common cold14,62,63
Unani formulations
Tiryaq-e-ArbaAristolochia longa, Commiphora myrrha, Gentiana lutea, Laurus nobilisAntidote, antispasmodic, and antiviral64–66
Arq-e-AjeebCamphor, menthol, Thymol,Antiviral and anti-inflammatory14,67–69
Khamira-e-BanafshaViola odorataAntiretroviral, anti-inflammatory, and effective for respiratory tract and chest infections14,70,71
Laooq-e-SapistanCordia myxa, Ziziphus jujubaAnti-inflammatory, antiviral, and effective for chest infection14,72–74
Habb-e-BukharBambusa Bambos, Cinchona officinalis, Tinospora cordifoliaAntimalarial, antiviral, and immune-boosting75–77
Siddha formulations
Nilavembu KudineerAndrographis paniculata, Chrysopogon zizanoides, Cyperus rotundus, Mollugo cerviana, Piper nigrum, Plectranthus vettiveroides, Santalum album, Trichosanthes cucumerina, Zingiber officinaleImmunomodulatory, anti-asthmatic, antimicrobial, anti-allergic, antiviral, and effective against chikungunya, dengue fever, malaria, typhoid, and viral fevers14,37,40,78–83
Adathodai ManapaguAdathoda vasicaImmune-boosting and for treating respiratory disorders84,85
Kabasura KudineerAnacyclus pyrethrum, Andrographis paniculata, Clerodendron serratum, Coleus aromaticus, Costus speciosus, Cyperus rotundus, Hygrophila auriculata, Justicia adhatoda, Piper longum, Sida acuta, Syzygium aromaticum, Terminalia chebula, Tinospora cordifolia, Tragia involucrata, Zingiber officinaleAnti-allergic, antiviral, immunomodulatory, and effective for respiratory tract infections14,37,57,82,83

COVID-19, coronavirus disease 2019.

Ayurvedic formulations

Ayurvedic formulations recommended by AYUSH include AYUSH Kwath, Samshamani Vati, AYUSH-64, Agasthya Hareetaki, and Anuthaila.14 The AYUSH Kwath formulation contains four herbs (Cinnamomum zeylanicum, stem barks; Ocimum sanctum, leaves; Piper nigrum, fruits; and Zingiber officinale, rhizomes) and is available in the market as powder and tablet forms.14,86 These herbs are immune boosters and are effective natural solutions to many viral diseases.36–38 Therefore, the Ministry of AYUSH has approved the use of AYUSH Kwath against COVID-19 infection.39–41

Samshamani Vati is the aqueous extract from the medicinal plant Tinospora cordifolia and is useful against all types of fevers.14,42 Further, this Ayurvedic formulation has antipyretic, immunomodulatory, antiviral, and anti-inflammatory effects.42–45 AYUSH recommended a 500-mg Samshamani Vati tablet twice daily with warm water for 15 days for asymptomatic COVID-19 patients and mild COVID-19-positive individuals.87

AYUSH-64 is a tablet containing Picrorhiza kurroa (rhizomes), Swertia chirayita (whole plant), Alstonia scholaris (bark), and Caesalpinia crista (seed pulp).14 Its constituents are reported to have antiviral, anti-asthmatic, and immune-boosting properties.46–50 As AYUSH-64 has antimalarial action,51 it is proposed to be effective against populations with a high risk of coronavirus infection. Hence, AYUSH recommended this tablet for COVID-19 patients (two 500-mg tablets twice daily for 30 days in warm water for asymptomatic individuals and two 500-mg tablets three times daily for 30 days in warm water for mild COVID-19-positive individuals).87

Agasthya Hareetaki is a Rasayana popularly known as Avaleha kalpana. This is a formulation of more than 15 herbal ingredients, including Inula racemosa, Piper longum, Piper chaba, Mucuna prurita, Sida cordifolia, Aegle marmelos, Plumbago zeylanica, Terminalia chebula, Hordeum vulgare, Clerodendron serratum, Achyranthes aspera, Hedychium spicatum, Convolvulus pluricaulis, Tribulus terrestris, Solanum surattense, Solanum indicum, Uraria picta, Desmodium gangeticum, Premna mucronata, Stereospermum suaveolens, Gmelina arborea, and Oroxylum indicumand commonly used against respiratory tract infections.14,88 As its ingredients have anti-asthmatic, anti-oxidant, anti-inflammatory, antiviral, and immunomodulatory activities, this formulation is suggested for the management of COVID-19-related symptoms.52–61 AYUSH recommended 5 g of Agasthya Hareetaki twice daily with warm water for COVID-19 symptom management.89

Anuthaila is an Ayurvedic oil preparation of about 25 herbs, including Aquilaria agallocha (heartwood), Aegle marmelos (root), Berberis aristata (stem), Asparagus racemosus (root), Cedrus deodara (heartwood), Cinnamomum zeylanicum (stem bark), Cinnamomum tamala (leaf), Coleus vettiveroides (root), Cyperus rotundus (rhizome), Desmodium gangeticum (whole plant), Cyperus scariosus (rhizome), Embelia ribes (fruits), Elettaria cardamomum (seed), Glycyrrhiza glabra (root), Hemidesmus indicus (root), Nelumbo nucifera (flower), Leptadenia reticulata (root), Nymphaea stellata (flower), Santalum album (heartwood), Pluchea lanceolata (root), Solanum indicum (whole plant), Uraria Picta (whole plant), Solanum surattense (whole plant), Vetiveria zizanioides (root), Sesamum indicum (oil), and Vitex negundo (seed).90 The ingredients L. reticulata and S. indicum are effective against asthma, allergic responses, bronchitis, cough, throat trouble, fever, migraine, malaria, respiratory infections, and the common cold, thus justifying the use of Anuthaila for COVID-19.14,62,63 Further, since ancient times, Anuthaila oil has been used for nasya, to cure skin dryness, graying of hair, a disorder of body parts above the clavicle, wasting in the cervical region, and emaciation of the shoulder and chest muscles.90 AYUSH recommended two drops of Anuthaila daily in the morning in each nostril for the management of COVID-19 symptoms.89

In addition to the aforementioned Ayurvedic formulations, the Ministry of AYUSH (Government of India) highlighted the Ayurvedic health supplement chyawanprash as an immunity booster during the COVID-19 pandemic. Chyawanprash is a synergistic combination of around fifty medicinal herbs and spices. Apart from its role as an immune booster, this blend has beneficial anti-inflammatory, anti-oxidant, and cytoprotective effects and is also known to improve the health of the respiratory system.91–93

Unani formulations

Unani formulations recommended by AYUSH include Tiryaq-e-Arba, Arq-e-Ajeeb, Khamira-e-Banafsha, Laooq-e-Sapistan, and Habb-e-Bukhar.14,94 Tiryaq-e-Arba contains four herbal ingredients (Laurus nobilis, Gentiana lutea, Commiphora myrrha, and Aristolochia longa) and has antidote and antispasmodic properties.64 Its ingredients are reported as effective antiviral agents, including anti-SARS-CoV activity.65,66 Thus, Tiryaq-e-Araba could emerge as an active antiviral medicine against COVID-19. AYUSH recommended using the Tiryaq-e-Arba formulation at a dose of 3–5 g with lukewarm water.94

Arq-e-Ajeeb is a liquid formulation of menthol, thymol, and camphor.14 Thymol has antiviral activity, particularly for the herpes simplex virus.67,68 Menthol is reported for its anti-inflammatory efficacy.69 The Unani physicians used Arq-e-Ajeeb for treating Swine flu and set a very successful treatment history.14 These shreds of evidence enhance the possibility of using Arq-e-Ajeeb against COVID-19; thus, AYUSH recommended inhaling 2–5 drops of Arq-e-Ajeeb for respiratory tract infection.94

Khamira-e-Banafsha is a semi-solid Unani preparation that is primarily used as an expectorant for colds and coughs. It is also effective for respiratory tract and chest infections, whooping cough, bronchitis, fever, and other conditions. It is made by adding the decoction of Viola odorata flowers to a base of sugar or sugar with honey.14 Moreover, research has shown that V. odorata can reduce the viral load and boost the effectiveness of antiretroviral medications.70 It is also effective for the prevention of lung damage and is suggested as a safer medicinal agent in the treatment of inflammatory conditions of the lung.71 The literature stated above is in favor of using it to manage COVID-19. AYUSH recommended Khamira-e-Banafsha for dry cough at a dose of 5 g and 10 g twice daily for those aged 6–12 years old and above 12 years old, respectively.94

Laooq-e-Sapistan is a semisolid, sugar-based polyherbal preparation of Unani medicine. It has been proven to be effective against whooping cough, phlegm, and colds. It further reduces inflammation of the pharynx and tonsils. The main ingredient is the sticky, jelly-like mass of ripened fruit of Cordia myxa, which has been shown to have anti-inflammatory and antichest infection properties.14,72 Ziziphus fruit (Ziziphus jujuba), another important constituent, contains betulinic acid, which is reported to have antiviral efficacy.14,73,74 These literature reports thus support the exploration of Laooq-e-Sapistan for COVID-19 infection, and AYUSH recommended Laooq-e-Sapistan for dry cough (5 g and 10 g twice daily for those aged 6–12 years old and above 12 years old, respectively).94

Habb-e-Bukhar is a polyherbal Unani formulation in tablet form that is given to treat malarial fever and elephantiasis.14 It is made up of three ingredients (Bambusa Bambos, Cinchona officinalis, and Tinospora cordifolia). The ingredient C. officinalis is rich in the alkaloids quinine, quinidine, cinchonidine, and cinchonine, and these natural products are potent antimalarial agents.75T. cordifolia, another constituent of Habb-e-Bukhar, is reported to be an effective antiviral agent against the herpes simplex virus and also to have immune-boosting efficacy.76,77 Thus, Habb-e-Bukhar is recommended by AYUSH to be taken twice daily for high fever (250 mg for those aged 6–12 years old and 500 mg for those older than 12 years old).94

Siddha formulations

Siddha formulations recommended by AYUSH include Nilavembu Kudineer, Adathodai Manapagu, and Kabasura Kudineer.14 Nilavembu Kudineer is a polyherbal formulation containing Andrographis paniculata (whole plant), Chrysopogon zizanoides (root), Santalum album (bark), Zingiber officinale (rhizome), Piper nigrum (fruit), Cyperus rotundus (root tuber), Mollugo cerviana (whole plant), Plectranthus vettiveroides (root), and Trichosanthes cucumerina (whole plant).78 It plays a protective role against chikungunya and dengue fever and also acts as an immunomodulator.79 Recent studies have revealed its efficacy as an antimicrobial and antiviral remedy, which makes this formulation suitable to treat malaria, typhoid, and viral fevers.14,78,80 Research also has shown that most of its components are immune-boosting, antiviral, anti-asthmatic, and anti-allergic agents.37,40,81–83

Adathodai Manapagu is composed of the leaves of Adathoda vasica, which contain alkaloids like vasicine—the active ingredient in many cough syrups.14 This herb has been a well-established Indian traditional medicine since ancient times, particularly for treating various respiratory disorders.84 Its extract further enhances the host immunity.85

Kabasura Kudineer is another Siddha formulation that works well for common respiratory ailments like the flu and cold. In addition, Siddha practitioners suggest Kabasura Kudineer for fever, severe phlegm, and dry cough.14 It is made up of 15 herbal ingredients, including Zingiber officinale (rhizome), Syzygium aromaticum (flower bud), Piper longum (fruit), Tragia involucrate (root), Hygrophila auriculata (root), Anacyclus pyrethrum(root), Terminalia chebula (fruit rind), Coleus aromaticus (leaf), Justicia adhatoda (leaf), Costus speciosus (root), Clerodendron serratum (root), Tinospora cordifolia (stem), Andrographis paniculata (whole plant), Cyperus rotundus (root tuber), and Sida acuta (root).78 These ingredients have a unique role in treating respiratory tract infections, allergies, and viruses, and they have an immunomodulatory capacity.37,57,82,83 Hence, the Ministry of AYUSH advised using Kabasura Kudineer to treat COVID-19 symptoms. AYUSH suggested Nilavembu Kudineer and Kaba Sura Kudineer as antiviral medications (60 mL, twice a day after food) and Adathodai Manapagu (for adults: 10–20 mL with warm water, twice a day after food) for the management of COVID-19-related symptoms.95

Formulations from traditional Chinese medicine

Chinese traditional medicine is also a collection of multi-ingredient herbal remedies and has been well known for the well-being of humans, notably for treating infectious diseases since ancient times.96 When the COVID-19 outbreak first started, herbal remedies were extensively discussed and researched across China to reduce the spike in the number of infections. Its efficacy in reducing the severity of COVID-19 has been endorsed by frontline healthcare workers and the Chinese regulatory agency.24 More recently, researchers have presented scientific evidence supporting the impact of these herbal remedies on COVID-19 control. Lianhuaqingwen is a traditional Chinese mixture of 13 herbs and is well known for treating fever, fatigue, cough, influenza, pneumonia, bronchitis, and the early stage of measles. As a result, the Chinese National Health Commission suggested using this herbal remedy to manage or treat COVID-19.97,98 The remarkable in vitro antiviral activities of seven (forsythoside A, arctiin, isoliquiritigenin, gallic acid, kaempferol, secoxyloganin, and rutin) among 61 compounds from the Lianhuaqingwen herbal mixture, with IC50 values from 4.9 ± 0.1 µg/mL (kaempferol) to 47.8 ± 1.5 µg/mL (secoxyloganin), have been reported.99 Later, the anti-SARS-CoV-2 activity of the Lianhuaqingwen herbal mixture in Vero E6 cells was assessed by cytopathic effect inhibition and plaque reduction approaches, and it was observed that the SARS-CoV-2 replication in Vero E6 cells was inhibited by this herbal blend (IC50: 411.2 µg/mL). Additionally, they demonstrated that the mixture can dose-dependently inhibit the production of proinflammatory cytokines such as interleukin 6, tumor necrosis factor-alpha, chemokine ligand 2/monocyte chemoattractant protein 1, and C-X-C motif chemokine ligand 10.97

A combination strategy of lopinavir/ritonavir (Kaletra®) and arbidol with Shufeng Jiedua Chinese traditional medicine was tested in four COVID-19 patients. Following treatment, three of the patients reported improvements in pneumonia-related symptoms. Two of them were discharged after becoming COVID-19 negative, and one of them was COVID-19 negative at the first test. There also was improvement in the remaining patients with severe pneumonia.100 Most recently, it was found that the Chinese herbal remedy Liu-Shen capsules inhibited SARS-CoV-2 viral infection through downregulation of the expression of inflammatory cytokines and regulation of the nuclear factor kappa B/mitogen-activated protein kinase signaling pathway in vitro.101

The medicinal plants (in terms of extracts) and their herbal formulations against COVID-19 infection are schematically illustrated in Figure 3.

Schematic representation of medicinal plants (in terms of extracts) and their herbal formulations against COVID-19.
Fig. 3  Schematic representation of medicinal plants (in terms of extracts) and their herbal formulations against COVID-19.

COVID-19, coronavirus disease 2019.

Conclusion

Herbal medicine interventions are still seen as potential solutions to prevent and/or cure several ailments, and now the focus is on COVID-19. Herbal extracts contain a vast array of natural components that are underutilized in conventional therapies and might potentially serve as an endless source of therapeutic materials. Natural-origin chemicals can now be used more than in the past decades, largely as nutritional supplements and nutraceuticals, owing to new developments in science and medicine. This review, which examined COVID-19 from different angles in terms of medicinal plants, their extracts, and formulations, will be useful because there is growing interest in discovering treatments for long-term symptom relief and immunity-boosting to combat COVID-19. This review thus highlighted that traditional medicine formulations and extracts with active ingredients can be explored as a potential source to develop natural anti-SARS-CoV-2 drugs. Further experimental research is suggested to prove the detailed efficacy of these extracts and herbal formulations against COVID-19. A comprehensive approach needs to be used to examine their toxicity and consumption duration. Furthermore, novel methods of processing and formulation may enhance their solubility, transport mechanisms, and therapeutic properties, enabling their adaptation as antiviral functional foods and medications. Furthermore, novel strategies for the characterization of active phytochemicals of these extracts and formulations need to be devised for developing natural medications to treat COVID-19. Herbal extracts and formulations may have synergistic health benefits (anti-allergic, antiviral, anticancer, anti-inflammatory, etc.) due to naturally occurring phytochemical combinations; this is something to consider, but further research is needed.

Abbreviations

ACE2: 

angiotensin-converting enzyme-2

CAM: 

complementary and alternative medicine

COVID-19: 

coronavirus disease 2019

E: 

envelope

HSPA5: 

heat shock protein A5

M: 

membrane

MERS-CoV: 

Middle East respiratory syndrome-related coronavirus

N: 

nucleocapsid

ORFs: 

open reading frames

PLpro: 

papain-like protease

RdRp: 

RNA-dependent RNA polymerase

SARS-CoV-2: 

Severe Acute Respiratory Syndrome-related Coronavirus 2

S: 

spike

TMPRSS2: 

Transmembrane protease serine 2

3CLpro: 

chymotrypsin-like protease

Declarations

Acknowledgement

The authors would like to acknowledge the Indian Institute of Science, Bengaluru, India for the entire infrastructure and support. D. Sruthi would like to acknowledge the Department of Health Research (DHR), Government of India, New Delhi, for her award of the Young Scientist-HRD scheme (YSS/2019/000035/PRCYSS). D. Sruthi is also grateful to the Science and Engineering Research Board (SERB), Department of Science and Technology, Government of India, New Delhi, for her award of the National post-doctoral Fellowship (PDF/2017/000339).

Data sharing statement

The data used in support of the findings of this study are available from the corresponding author upon request.

Funding

There is nothing to declare.

Conflict of interest

The authors declare no conflicts of interest, financial or otherwise.

Authors’ contributions

Conceptualization, data curation, methodology, writing, reviewing, and editing original draft (DS); writing, reviewing, and editing original draft and reference formatting (JPJ); figure preparation, reference formatting, reviewing, and editing original draft (MD); reviewing and editing original draft (SPD); supervision (CJ).

References

  1. Jeon SR, Kang JW, Ang L, Lee HW, Lee MS, Kim TH. Complementary and alternative medicine (CAM) interventions for COVID-19: An overview of systematic reviews. Integr Med Res 2022;11(3):100842 View Article PubMed/NCBI
  2. Sruthi D, Dhanalakshmi M, Rao HCY, Parthasarathy R, Deepanraj SP, Jayabaskaran C. Curative potential of high-value phytochemicals on COVID-19 infection. Biochemistry (Mosc) 2023;88(1):64-72 View Article PubMed/NCBI
  3. Sharma V, Rai H, Gautam DNS, Prajapati PK, Sharma R. Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant. J Med Virol 2022;94(5):1876-1885 View Article PubMed/NCBI
  4. Varghese R, Kumar D, Sharma R. Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?. Hum Cell 2023;36(3):1218-1221 View Article PubMed/NCBI
  5. Varghese R, Pai S, Kumar D, Sharma R. SARS-CoV-2 XBB.1.16 variant: India in focus?. J Med Virol 2023;95(5):e28829 View Article PubMed/NCBI
  6. Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. Viruses 2023;15(1):167 View Article PubMed/NCBI
  7. Oladele JO, Ajayi EI, Oyeleke OM, Oladele OT, Olowookere BD, Adeniyi BM, et al. A systematic review on COVID-19 pandemic with special emphasis on curative potentials of Nigeria based medicinal plants. Heliyon 2020;6(9):e04897 View Article PubMed/NCBI
  8. Bjorklund G, Lysiuk R, Butnariu M, Lenchyk L, Sharma V, Sharma R, et al. Low prevalence of COVID-19 in Laos and Cambodia: Does diet play a role?. Acta Medica Leopoliensia 2022;28:161-180 View Article
  9. Rahman MM, Shohag S, Islam MR, Akhter S, Mim SA, Sharma R, et al. An insight into COVID-19 and traditional herbs: bangladesh perspective. Med Chem 2023;19(4):361-383 View Article PubMed/NCBI
  10. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7(1):4 View Article PubMed/NCBI
  11. DU HZ, Hou XY, Miao YH, Huang BS, Liu DH. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP). Chin J Nat Med 2020;18(3):206-210 View Article PubMed/NCBI
  12. Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of COVID-19: the Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020;49(2):147-157 View Article PubMed/NCBI
  13. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020;14(1):69-71 View Article PubMed/NCBI
  14. Ahmad S, Zahiruddin S, Parveen B, Basist P, Parveen A, Gaurav, et al. Indian medicinal plants and formulations and their potential against COVID-19-preclinical and clinical research. Front Pharmacol 2020;11:578970 View Article PubMed/NCBI
  15. Reddy KRC, Sahni C, Singh R, Chandana H, Sharma R. Ayurvedic medicines in alleviating the symptoms of SARS-CoV-2 omicron variant in North Indian population: a regional genomic study. Drug Metab Pers Ther 2023;38(3):289-291 View Article PubMed/NCBI
  16. Niemi MEK, Daly MJ, Ganna A. The human genetic epidemiology of COVID-19. Nat Rev Genet 2022;23(9):533-546 View Article PubMed/NCBI
  17. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int. Accessed December 18, 2023
  18. Chojnacka K, Witek-Krowiak A, Skrzypczak D, Mikula K, Młynarz P. Phytochemicals containing biologically active polyphenols as an effective agent against Covid-19-inducing coronavirus. J Funct Foods 2020;73:104146 View Article PubMed/NCBI
  19. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis 2020;1866(10):165878 View Article PubMed/NCBI
  20. Bhuiyan FR, Howlader S, Raihan T, Hasan M. Plants metabolites: possibility of natural therapeutics against the COVID-19 pandemic. Front Med (Lausanne) 2020;7:444 View Article PubMed/NCBI
  21. Benarba B, Pandiella A. Medicinal plants as sources of active molecules against COVID-19. Front Pharmacol 2020;11:1189 View Article PubMed/NCBI
  22. Adhikari B, Marasini BP, Rayamajhee B, Bhattarai BR, Lamichhane G, Khadayat K, et al. Potential roles of medicinal plants for the treatment of viral diseases focusing on COVID-19: A review. Phytother Res 2021;35(3):1298-1312 View Article PubMed/NCBI
  23. Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med 2020;28(2):174-184 PubMed/NCBI
  24. Huang J, Tao G, Liu J, Cai J, Huang Z, Chen JX. Current prevention of COVID-19: natural products and herbal medicine. Front Pharmacol 2020;11:588508 View Article PubMed/NCBI
  25. Abdullahi A, Tijjani A, Abubakar AI, Khairulmazmi A, Ismail MR. Herbal biomolecules in healthcare applications. UK: Elsevier Academic Press; 2022, 381-406 View Article
  26. Kim DW, Seo KH, Curtis-Long MJ, Oh KY, Oh JW, Cho JK, et al. Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia. J Enzyme Inhib Med Chem 2014;29(1):59-63 View Article PubMed/NCBI
  27. Park JY, Kim JH, Kim YM, Jeong HJ, Kim DW, Park KH, et al. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases. Bioorg Med Chem 2012;20(19):5928-5935 View Article PubMed/NCBI
  28. Ryu YB, Jeong HJ, Kim JH, Kim YM, Park JY, Kim D, et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition. Bioorg Med Chem 2010;18(22):7940-7947 View Article PubMed/NCBI
  29. Wen CC, Shyur LF, Jan JT, Liang PH, Kuo CJ, Arulselvan P, et al. Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication. J Tradit Complement Med 2011;1(1):41-50 View Article PubMed/NCBI
  30. Goswami D, Kumar M, Ghosh SK, Das A. Natural product compounds in Alpinia officinarum and ginger are pot ent SARS-CoV-2 papain like protease inhibitors. chemRxiv[preprint] 2020 View Article
  31. Pandya M, Shah S, M D, Juneja T, Patel A, Gadnayak A, et al. Unravelling vitamin B12 as a potential inhibitor against SARS-CoV-2: A computational approach. Inform Med Unlocked 2022;30:100951 View Article PubMed/NCBI
  32. Rahman MM, Islam MR, Akash S, Mim SA, Rahaman MS, Emran TB, et al. In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective. Front Cell Infect Microbiol 2022;12:929430 View Article PubMed/NCBI
  33. Koshak AE, Koshak EA, Mobeireek AF, Badawi MA, Wali SO, Malibary HM, et al. Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial. Complement Ther Med 2021;61:102769 View Article PubMed/NCBI
  34. Ravishankar B, Shukla VJ. Indian systems of medicine: a brief profile. Afr J Tradit Complement Altern Med 2007;4(3):319-337 View Article PubMed/NCBI
  35. Sharma R, Prajapati PK. Remarks on “herbal immune booster-induced liver injury in the COVID-19 pandemic - a case series”. J Clin Exp Hepatol 2022;12(1):247-248 View Article PubMed/NCBI
  36. Bhalla G, Kaur S, Kaur J, Kaur R, Raina P. Antileishmanial and immunomodulatory potential of Ocimumsanctum Linn. and Cocosnucifera Linn. in murine visceral leishmaniasis. J Parasit Dis 2017;41(1):76-85 View Article PubMed/NCBI
  37. Carrasco FR, Schmidt G, Romero AL, Sartoretto JL, Caparroz-Assef SM, Bersani-Amado CA, et al. Immunomodulatory activity of Zingiber officinale Roscoe, Salvia officinalis L. and Syzygium aromaticum L. essential oils: evidence for humor- and cell-mediated responses. J Pharm Pharmacol 2009;61(7):961-967 View Article PubMed/NCBI
  38. Niphade SR, Asad M, Chandrakala GK, Toppo E, Deshmukh P. Immunomodulatory activity of Cinnamomum zeylanicum bark. Pharm Biol 2009;47:1168-1173 View Article
  39. Ghoke SS, Sood R, Kumar N, Pateriya AK, Bhatia S, Mishra A, et al. Evaluation of antiviral activity of Ocimum sanctum and Acacia arabica leaves extracts against H9N2 virus using embryonated chicken egg model. BMC Complement Altern Med 2018;18(1):174 View Article PubMed/NCBI
  40. Mair CE, Liu R, Atanasov AG, Schmidtke M, Dirsch VM, Rollinger JM. Antiviral and anti-proliferative in vitro activities of piperamides from black pepper. Planta Med 2016;82:S1-S381 View Article
  41. Katoch P, Raina K, Sharma R, Sharma R, Chaudhary A. AYUSH Kwath: a major contribution of ayurveda in preventing COVID- 19 infection. Curr Drug Ther 2024;19:60-80 View Article
  42. Patgiri B, Umretia BL, Vaishnav PU, Prajapati PK, Shukla VJ, Ravishankar B. Anti-inflammatory activity of Guduchi Ghana (aqueous extract of Tinospora Cordifolia Miers.). Ayu 2014;35(1):108-110 View Article PubMed/NCBI
  43. Sachan S, Dhama K, Latheef SK, Samad HA, Mariappan AK, Munuswamy P, et al. Immunomodulatory Potential of Tinospora cordifolia and CpG ODN (TLR21 Agonist) against the Very Virulent, Infectious Bursal Disease Virus in SPF Chicks. Vaccines (Basel) 2019;7(3):106 View Article PubMed/NCBI
  44. Alsuhaibani S, Khan MA. Immune-stimulatory and therapeutic activity of tinospora cordifolia: double-edged sword against salmonellosis. J Immunol Res 2017;2017:1787803 View Article PubMed/NCBI
  45. More P, Pai K. Immunomodulatory effects of Tinospora cordifolia (Guduchi) on macrophage activation. Biol Med 2011;3:134-140
  46. Woo SY, Win NN, Noe Oo WM, Ngwe H, Ito T, Abe I, et al. Viral protein R inhibitors from Swertia chirata of Myanmar. J Biosci Bioeng 2019;128(4):445-449 View Article PubMed/NCBI
  47. Win NN, Kodama T, Lae KZW, Win YY, Ngwe H, Abe I, et al. Bis-iridoid and iridoid glycosides: Viral protein R inhibitors from Picrorhiza kurroa collected in Myanmar. Fitoterapia 2019;134:101-107 View Article PubMed/NCBI
  48. Panda SK, Padhi L, Leyssen P, Liu M, Neyts J, Luyten W. Antimicrobial, anthelmintic, and antiviral activity of plants traditionally used for treating infectious disease in the similipal biosphere reserve, Odisha, India. Front Pharmacol 2017;8:658 View Article PubMed/NCBI
  49. Sehgal R, Chauhan A, Gilhotra UK, Gilhotra A. In-vitro and in-vivo evaluation of antiasthmatic activity of Picrorhiza kurroa plant. Int J Pharm Sci Res 2013;4:3440-3443
  50. Siddiqui NA, Singh S, Siddiquei MM, Khan TH. Immunomodulatory effect of Withania somnifera, Asparagus racemosus and Picrorhiza kurroa roots. Int J Pharmacol 2012;8:108-114 View Article
  51. Shankar R, Deb S, Sharma BK. Antimalarial plants of northeast India: An overview. J Ayurveda Integr Med 2012;3(1):10-16 View Article PubMed/NCBI
  52. Sruthi D, Jagannathan A, Chandran AB, Rao HCY, Jayabaskaran C. Chromatography-mass spectrometry based chemical profiling of Mucuna pruriens (L.) DC. and its beneficial effect against hydrogen peroxide-induced oxidative stress in HEK-293T cells and breast cancer cells. S Afr J Bot 2023;159:85-97 View Article
  53. Sruthi D, Zachariah TJ. In vitro antioxidant activity and cytotoxicity of sequential extracts from selected black pepper (Piper nigrum L.) varieties and Piper species. Int Food Res J 2017;24:75-85 View Article
  54. Jiang ZY, Liu WF, Zhang XM, Luo J, Ma YB, Chen JJ. Anti-HBV active constituents from Piper longum. Bioorg Med Chem Lett 2013;23(7):2123-2127 View Article PubMed/NCBI
  55. Lampariello LR, Cortelazzo A, Guerranti R, Sticozzi C, Valacchi G. The magic velvet bean of mucuna pruriens. J Tradit Complement Med 2012;2(4):331-339 View Article PubMed/NCBI
  56. Jain A, Choubev S, Singour PK, Rajak H, Pawar RS. Sida cordifolia (Linn) - an overview. J Appl Pharm Sci 2011;1:23-31
  57. Kumar S, Kamboj J, Sharma S, Suman. Overview for various aspects of the health benefits of Piper longum linn. fruit. J Acupunct Meridian Stud 2011;4(2):134-140 View Article PubMed/NCBI
  58. Pathak M, Vyas H, Vyas MK. A clinical trial of Pippali (Piper longum Linn.) with special reference to Abheshaja. Ayu 2010;31(4):442-446 View Article PubMed/NCBI
  59. Vadnere GP, Gaud RS, Singhai AK, Somani RS. Effect of Inula racemosa root extract on various aspects of asthma. Pharmacology online 2009;2:84-94
  60. Balasubramanian G, Sarathi M, Kumar SR, Hameed ASS. Screening the antiviral activity of Indian medicinal plants against white spot syndrome virus in shrimp. Aquaculture 2007;263:15-19 View Article
  61. Mouhajir F, Hudson JB, Rejdali M, Towers GHN. Multiple antiviral activities of endemic medicinal plants used by Berber peoples of Morocco. Pharm Biol 2001;39:364-374 View Article
  62. Mohanty SK, Swamy MK, Sinniah UR, Anuradha M. Leptadenia reticulata (Retz.) Wight & Arn. (Jivanti): botanical, agronomical, phytochemical, pharmacological, and biotechnological aspects. Molecules 2017;22(6):1019 View Article PubMed/NCBI
  63. Mukta N, Neeta PM. A review on sesame-an ethno medicinally significant oil crop. Int J Life Sci Pharma Res 2017;7:L58-L63
  64. Ansari S, Ahmad I, Ali M, Maaz M. “Tiryaq Arba” (A polyherbal Unani formulation) as prophylactic medicine against epidemics of acute respiratory viral infections. Middle East J Rehabil Health Stud 2020;7:e102965 View Article
  65. Aurori AC, Bobiş O, Dezmirean DS, Mărghitaş LA, Erler S. Bay laurel (Laurus nobilis) as potential antiviral treatment in naturally BQCV infected honeybees. Virus Res 2016;222:29-33 View Article PubMed/NCBI
  66. Loizzo MR, Saab AM, Tundis R, Statti GA, Menichini F, Lampronti I, et al. Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species. Chem Biodivers 2008;5(3):461-470 View Article PubMed/NCBI
  67. Sharifi-Rad J, Salehi B, Schnitzler P, Ayatollahi SA, Kobarfard F, Fathi M, et al. Susceptibility of herpes simplex virus type 1 to monoterpenes thymol, carvacrol, p-cymene and essential oils of Sinapis arvensis L., Lallemantia royleana Benth. and Pulicaria vulgaris Gaertn. Cell Mol Biol (Noisy-le-grand) 2017;63(8):42-47 View Article PubMed/NCBI
  68. Lai WL, Chuang HS, Lee MH, Wei CL, Lin CF, Tsai YC. Inhibition of herpes simplex virus type 1 by thymol-related monoterpenoids. Planta Med 2012;78(15):1636-1638 View Article PubMed/NCBI
  69. Zaia MG, Cagnazzo Td, Feitosa KA, Soares EG, Faccioli LH, Allegretti SM, et al. Anti-inflammatory properties of menthol and menthone in schistosoma mansoni infection. Front Pharmacol 2016;7:170 View Article PubMed/NCBI
  70. Gerlach SL, Chandra PK, Roy U, Gunasekera S, Göransson U, Wimley WC, et al. The membrane-active phytopeptide cycloviolacin o2 simultaneously targets HIV-1-infected cells and infectious viral particles to potentiate the efficacy of antiretroviral drugs. Medicines (Basel) 2019;6(1):33 View Article PubMed/NCBI
  71. Koochek MH, Pipelzadeh MH, Mardani H. The effectiveness of Viola odorata in the prevention and treatment of formalin-induced lung damage in the rat. J Herbs Spice Med Plants 2003;10:95-103 View Article
  72. Jamkhande PG, Barde SR, Patwekar SL, Tidke PS. Plant profile, phytochemistry and pharmacology of Cordia dichotoma (Indian cherry): a review. Asian Pac J Trop Biomed 2013;3(12):1009-1016 View Article PubMed/NCBI
  73. Sultana A, Khanam M, Rahman K, Sumbul. Traditional unani medicine in flu-like epidemics and COVID-19 during pregnancy: a literary research. CellMed 2021;11:20.1-24
  74. Hong EH, Song JH, Kang KB, Sung SH, Ko HJ, Yang H. Anti-Influenza Activity of Betulinic Acid from Zizyphus jujuba on Influenza A/PR/8 Virus. Biomol Ther (Seoul) 2015;23(4):345-349 View Article PubMed/NCBI
  75. Khan AA, Meena R, Devi Sri PM, Davis DJ, Ahmed NZ, Mageswari S, et al. Antimicrobial, hptlc and in-silico studies of habb-e- bukhar - widely used in unani system of medicine. Int J Recent Sci Res 2021;12:42788-42793
  76. Rastogi S, Pandey DN, Singh RH. COVID-19 pandemic: A pragmatic plan for ayurveda intervention. J Ayurveda Integr Med 2022;13(1):100312 View Article PubMed/NCBI
  77. Pruthvish R, Gopinatha SM. Antiviral prospective of Tinospora cordifolia on HSV-1. Int J Curr Microbiol App Sci 2018;7:3617-3624 View Article
  78. Mekala P, Murthy TRGK. Phytochemical screening and pharmacological update on Kabasura Kudineer Choornam and Nilavembu Kudineer Choornam. J Pharmacogn Phytochem 2020;9:1031-1036 View Article
  79. Jain J, Kumar A, Narayanan V, Ramaswamy RS, Sathiyarajeswaran P, Shree Devi MS, et al. Antiviral activity of ethanolic extract of Nilavembu Kudineer against dengue and chikungunya virus through in vitro evaluation. J Ayurveda Integr Med 2020;11(3):329-335 View Article PubMed/NCBI
  80. Mahadevan H, Palraj V. Literature review on Siddha herbal formulations (Kudineer) available for the management of dengue. Int J Pharmacol Clin Sci 2016;5:90-96 View Article
  81. Wintachai P, Kaur P, Lee RC, Ramphan S, Kuadkitkan A, Wikan N, et al. Activity of andrographolide against chikungunya virus infection. Sci Rep 2015;5:14179 View Article PubMed/NCBI
  82. Chang JS, Wang KC, Yeh CF, Shieh DE, Chiang LC. Fresh ginger (Zingiber officinale) has anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines. J Ethnopharmacol 2013;145(1):146-151 View Article PubMed/NCBI
  83. Jin JH, Lee DU, Kim YS, Kim HP. Anti-allergic activity of sesquiterpenes from the rhizomes of Cyperus rotundus. Arch Pharm Res 2011;34(2):223-228 View Article PubMed/NCBI
  84. Sampath Kumar KP, Bhowmik D, Tiwari P, Kharel R, Chiranjib. Indian traditional herbs Adhatoda vasica and its medicinal application. J Chem Pharm Res 2010;2:240-245
  85. Vinothapooshan G, Sundar K. Immunomodulatory activity of various extracts of Adhatoda vasica Linn. in experimental rats. African J Pharm Pharmacol 2011;5:306-310 View Article
  86. Gautam S, Gautam A, Chhetri S, Bhattarai U. Immunity against COVID-19: Potential role of Ayush Kwath. J Ayurveda Integr Med 2022;13(1):100350 View Article PubMed/NCBI
  87. Ministry of Ayush, Government of India. Guidelines for ayurveda practitioners for COVID-19 patients in home isolation. New Delhi: Ministry of Ayush; 2021
  88. Poudel S, Yadav MP, Pradeep. Agastya Haritaki Rasayana: A critical review. J Drug Deliv Ther 2019;9:486-491 View Article
  89. AYUSH Ministry of Health, Government of India. Corona Advisory-D.O. No. S. 16030/18/2019-NAM. New Delhi: Ministry of Ayush; 2020
  90. Meena AK, Rekha P, Perumal A, Ilavarasan R, Singh R, Srikant N, et al. Identification and estimation of bioactive constituents Negundoside, Berberine chloride, and Marmelosin by HPLC and HPTLC for development of quality control protocols for Ayurvedic medicated oil formulation. Futur J Pharm Sci 2021;7(1):171 View Article PubMed/NCBI
  91. Kakodkar P, Sharma R, Dubewar AP. Classical vs commercial: Is the ‘efficacy’ of chyawanprash lost when tradition is replaced by modernization?. J Ayurveda Integr Med 2021;12(4):751-752 View Article PubMed/NCBI
  92. Sharma R, Kakodkar P, Kabra A, Prajapati PK. Golden ager Chyawanprash with meager evidential base from human clinical trials. Evid Based Complement Alternat Med 2022;2022:9106415 View Article
  93. Sharma R, Martins N, Kuca K, Chaudhary A, Kabra A, Rao MM, et al. Chyawanprash: a traditional Indian bioactive health supplement. Biomolecules 2019;9(5):161 View Article PubMed/NCBI
  94. Ministry of Ayush, Government of India. Guidelines for UNANI practitioners for COVID-19. New Delhi: Ministry of Ayush; 2021
  95. Ministry of Ayush, Government of India. Guidelines for SIDDHA practitioners for COVID 19. New Delhi: Ministry of Ayush; 2021
  96. Weng JK. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives. Mol Plant 2020;13(6):803-807 View Article PubMed/NCBI
  97. Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020;156:104761 View Article PubMed/NCBI
  98. Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med 2017;17(1):130 View Article PubMed/NCBI
  99. Wang CH, Zhong Y, Zhang Y, Liu JP, Wang YF, Jia WN, et al. A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components. Mol Biosyst 2016;12(2):606-613 View Article PubMed/NCBI
  100. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020;14(1):64-68 View Article PubMed/NCBI
  101. Ma Q, Pan W, Li R, Liu B, Li C, Xie Y, et al. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway. Pharmacol Res 2020;158:104850 View Article PubMed/NCBI
Copyright © 2023 Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Future Integrative Medicine
  • pISSN 2993-5253
  • eISSN 2835-6357

Article Options

Metrics

Cite this Article

  • © 2024 Xia & He Publishing Inc.
  • Total visits : 2751398
  • Visits today : 2691
Back to Top

Medicinal Plant Extracts and Herbal Formulations: Plant Solutions for the Prevention and Treatment of COVID-19 Infection

Damodaran Sruthi, Janardhanan Pallikere Jishna, Menamadathil Dhanalakshmi, Shashikala Paranthaman Deepanraj, Chelliah Jayabaskaran
  • Reset Zoom
  • Download TIFF